Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial

Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial

Summary: Background: Impaired double strand DNA repair by homologous repair deficiency (HRD) leads to sensitivity to poly ADP ribose polymerase (PARP) inhibition. Poly-ADP ribose polymerase (PARP) inhibitors target HRD to induce synthetic lethality and are used routinely in the treatment of BRCA1 m...

Full description

Bibliographic Details
Main Authors: Dean A. Fennell, Catharine Porter, Jason Lester, Sarah Danson, Fiona Blackhall, Marianne Nicolson, Lisette Nixon, Georgina Gardner, Ann White, Gareth Griffiths, Angela Casbard
Format: Article
Language:English
Published: Elsevier 2022-10-01
Series:EClinicalMedicine
Subjects:
NSCLC
PARP
Olaparib
HRD
Placebo
Randomised
Online Access:http://www.sciencedirect.com/science/article/pii/S258953702200325X

Internet

http://www.sciencedirect.com/science/article/pii/S258953702200325X

Similar Items